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Since its presentation as an abstract in March 1995 (1) and its 
subsequent publication in August 1995 (2) the case-control 
study by Psaty et al. has generated controversy. Tl.eir results 
suggested that short-acting calcium channel blocking agents 
increased the rate of myocardial infarction in patients treated 
for hypertension. However, case-control studies cannot ad- 
dress this issue because of potential unrecognized bias; at 
best they are useful in generating a hypothesis (3). The 
potential for ~~isk&i~~g results is suggested by a recent 
case-control study that indicated that beta-adrenergic block- 
ing agents increase the rate of sudden death in patients 
treated for hypertension (4). 
The controversy was fueled by the report of Furbeg et al. 
(5), which reported the results of a meta-analysis of prospec- 
tive, randomized, placebo-controlled trials of short-acting 
nifedipine in patients with myocardial infarction and unstable 
angina. The results uggested that doses Xi0 mg/day increased 
mortality. Although criticized for a number of reasons (6,7), 
the data, together with other studies, suggest that short-acting 
cakium channel blockers hould not be used in postmyocardial 
infarction patients. The controversy regarding calcium channel 
blockers now seems to be debated at every major cardiology 
and hypertension meeting. Frequently, the debates are more 
theatrical than scientific. This has polarized opinion and in 
some cases led to severe undue criticism of the participants (8). 
The following represent some of my thoughts regarding the 
controversy: 
1. Case-control studies in hypertension cannot address the 
issue. Nevertheless, one should be cautious about using 
short-acting calcium channel blockers. 
2. Long-acting calcium channel blockers are effective in treat- 
ing hypertension and do not cause the cyclic pattern of 
hypotension and the reflex increase in catecholamine l vels 
that, for example, short-acting nifedipine causes. One gets 
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some reassurance r garding long-acting amlodipine from 
the PRAISE trial (9) and the neutral effect of felodipine in 
V-HEIT 3 (10). I personally am comfortable in using all 
long-acting calcium channel blockers in patients with hyper- 
tension. They are also very effective in vasospastic angina 
and exercise-induced angina. 
Table 1. Newer Trials of Calcium Channel Blockers 
Study/Agent Hypothesis 
Projected 
No. of 
Patients 
Primary 
End 
Points Comment 
NORDIL 
Nifedipine 
(Pfizer/Bayer 
A(3 
PREDIfl 
Diitiazem 
(Hoechst- 
Marion- 
Roussel) 
Compares 12,OlKl 
nifedipine 
with 
conventional 
therapy :o 
prcvept events 
Assess high 6.ooO- 
risk 7800 
population M. 
chlcxthalidone 
CONVINCE 
Verapamil Verapamil us. IS,0 
using a new thiazide or 
formulation. beta-blocker 
COER 
Covera-HS 
(Searle) 
cv A prohe design, 
mortality randomized trial 
and in 480 centers in 
morbidity. Norway and 
including Sweden. with an 
MI and average of 5 yr of 
stroke treatment 
Mortality. 
CV events 
(fatal and 
nonfatal) 
MI, 
stroke, 
death 
3.yr follow-up; 
enmllment of 
mild to modcrate 
hypertension at 
high risk in 30U 
ccntcrs 
Randomized, 
prospective 4- 
6-yT follow-up; 
targeting morning 
events by 
matching drug 
effect to natural 
circadian rhythm 
CONVINCE = Controlled Onset Verapamil Investigation of Cardiovascular 
Endpoims (Principal Investigator, Henry Black, Rosh presbyterian St Lukea 
Hospital, Chicago, Iiliiois); CV = cars MI = myoca&d infarction; 
NORDIL = Nordic Diltiazm Study (principal hwestigator, Lennart Harsson, 
Uppsala, Sweden); PREDICT = Prcqe&e Randomized Evahmtion of Diltiazem 
CD Trial (principal Imestigator, Wil l iam Applegate, University of Temxssee, 
Memphis). 
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3. The long-term safety and efficacy of calcium channel block- 
ers can only be addressed by long-term prospective trials, 
and such trials are under way. In addition to the five 
hypertension trials (HOT, STOP, ALLHAT, INSIGHT, 
EURO-SYST) and three heart failure trials (V-HEW III, 
PRAISE-2, MACH-l) listed in the editorial by Salim Yusuf 
(11): there are three newer trials of calcium channel block- 
ers (Table 1). Thus, the answer will be delayed; but I 
personally do not believe that the use of all calcium channel 
blockers hould be avoided, as some have suggested. I do 
agree, however. that short-acting calcium channel blockers 
are best avoided. Hopefully, the intensity of the controversy 
will diminish as the results of prospective, randomized trials 
become available. 
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